Hépato-Gastro & Oncologie Digestive
MENUCurrent progress in the management of digestive neuroendocrine tumors Volume 18, issue 5, Septembre-Octobre 2011
Figures
Hôpital Beaujon,
service de gastroentérologie-pancréatologie,
100, boulevard du Général-Leclerc,
92118 Clichy Cedex,
France
- Key words: neuroendocrine digestive tumors, WHO classification, surgery, targeted therapies, chemotherapy, embolization, somatostatin analogues, therapeutic strategy
- DOI : 10.1684/hpg.2011.0640
- Page(s) : 500-5
- Published in: 2011
Neuroendocrine digestive tumors should be described according to the 2010 WHO classification, based on cell proliferation index. The therapeutic management of pancreatic tumors has recently gained from the publication of two large randomized prospective trials using targeted therapies ( i.e. sunitinib 37,5 mg/day or everolimus 10 mg/day). The later drug is also effective (although not significantly) on tumors associated with the carcinoid syndrome. The French Thesaurus of Digestive Oncology was very recently updated. It provides management algorithms for each primary localization according to the presence or absence of metastases.